Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more
Medicenna Therapeutics Corp (MDNAF) - Total Liabilities
Latest total liabilities as of September 2025: $7.80 Million USD
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNAF) has total liabilities worth $7.80 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medicenna Therapeutics Corp - Total Liabilities Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medicenna Therapeutics Corp Competitors by Total Liabilities
The table below lists competitors of Medicenna Therapeutics Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Farmers and Merchants Bancshares Inc
PINK:FMFG
|
USA | $807.30 Million |
|
Pruksa Holding Public Company Limited
F:2PR3
|
Germany | €21.60 Billion |
|
DK-Lok Corporation
KQ:105740
|
Korea | ₩84.03 Billion |
|
Samick Thk
KO:004380
|
Korea | ₩257.11 Billion |
|
JW Shinyak Corporation
KQ:067290
|
Korea | ₩26.02 Billion |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
Taiwan | NT$77.78 Million |
|
Bourse Direct SA
PA:BSD
|
France | €1.20 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Medicenna Therapeutics Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medicenna Therapeutics Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual total liabilities of Medicenna Therapeutics Corp from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $9.29 Million | -33.39% |
| 2024-03-31 | $13.94 Million | +100.33% |
| 2023-03-31 | $6.96 Million | +165.55% |
| 2022-03-31 | $2.62 Million | -36.18% |
| 2021-03-31 | $4.11 Million | +122.34% |
| 2020-03-31 | $1.85 Million | -28.15% |
| 2019-03-31 | $2.57 Million | +16.18% |
| 2018-03-31 | $2.21 Million | -71.73% |
| 2017-03-31 | $7.83 Million | +122.97% |
| 2016-03-31 | $3.51 Million | +1102.65% |
| 2015-03-31 | $291.87K | -64.83% |
| 2014-03-31 | $829.89K | -- |